Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.

about

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.

Item

http://www.wikidata.org/entity/Q51034578

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@en

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@nl

type

Item

label

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@en

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@nl

prefLabel

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@en

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@nl

P1476

Panobinostat as Pan-deacetylas ...... Progress and Future Prospects.

@en

P2093

Avineesh Singh

http://www.w3.org/2001/XMLSchema#string

Deepak K Jain

http://www.w3.org/2001/XMLSchema#string

Harish Rajak

http://www.w3.org/2001/XMLSchema#string

Preeti Patel

http://www.w3.org/2001/XMLSchema#string

Vijay K Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic and epigenetic alterations in pancreatic carcinogenesis

Silencing of the transforming growth factor-beta (TGFbeta) receptor II by Kruppel-like factor 14 underscores the importance of a negative feedback mechanism in TGFbeta signaling

Histone deacetylase inhibitors: Potential in cancer therapy

Genome regulation by polycomb and trithorax proteins

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)

Anticancer activities of histone deacetylase inhibitors

Clinical Toxicities of Histone Deacetylase Inhibitors.

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.

P2888

s40487-016-0023-1

P304

73-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40487-016-0023-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28261641

http://www.w3.org/2001/XMLSchema#string

P932

5315073

http://www.w3.org/2001/XMLSchema#string